Interleukin 1 Receptor Antagonist Protein
"Interleukin 1 Receptor Antagonist Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A ligand that binds to but fails to activate the INTERLEUKIN 1 RECEPTOR. It plays an inhibitory role in the regulation of INFLAMMATION and FEVER. Several isoforms of the protein exist due to multiple ALTERNATIVE SPLICING of its mRNA.
| Descriptor ID |
D053590
|
| MeSH Number(s) |
D12.644.276.374.460 D12.776.467.374.460 D23.529.374.460
|
| Concept/Terms |
Interleukin 1 Receptor Antagonist Protein- Interleukin 1 Receptor Antagonist Protein
- IL1 Febrile Inhibitor
- Febrile Inhibitor, IL1
- IL-1Ra
- Urine-Derived IL1 Inhibitor
- IL1 Inhibitor, Urine-Derived
- Urine Derived IL1 Inhibitor
- IL-1 Inhibitor, Urine
- IL 1 Inhibitor, Urine
- Urine IL-1 Inhibitor
- Interleukin 1 Inhibitor, Urine
|
Below are MeSH descriptors whose meaning is more general than "Interleukin 1 Receptor Antagonist Protein".
Below are MeSH descriptors whose meaning is more specific than "Interleukin 1 Receptor Antagonist Protein".
This graph shows the total number of publications written about "Interleukin 1 Receptor Antagonist Protein" by people in this website by year, and whether "Interleukin 1 Receptor Antagonist Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2012 | 1 | 1 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 2 | 3 | 5 |
| 2017 | 13 | 4 | 17 |
| 2018 | 11 | 9 | 20 |
| 2019 | 6 | 4 | 10 |
| 2020 | 18 | 13 | 31 |
| 2021 | 13 | 11 | 24 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin 1 Receptor Antagonist Protein" by people in Profiles.
-
Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis. Rheumatology (Oxford). 2021 12 01; 60(12):5527-5537.
-
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021 10; 27(10):1752-1760.
-
COVID-19 Disease in Patients With Recurrent Pericarditis During Treatment With Anakinra: Comment on the Article by Navarro-Millán et al. Arthritis Rheumatol. 2021 08; 73(8):1562-1563.
-
Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions. Mol Cells. 2021 Jun 30; 44(6):408-421.
-
Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J. 2021 Jun 29; 19(1):98.
-
Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma. Eur J Intern Med. 2021 08; 90:107-108.
-
Anti-COVID-19 measurements for hidradenitis suppurativa patients. Exp Dermatol. 2021 06; 30 Suppl 1:18-22.
-
Multisystem inflammatory syndrome in adults: A rare sequela of SARS-CoV-2 infection. Int J Infect Dis. 2021 Jul; 108:209-211.
-
Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications. Epilepsy Res. 2021 08; 174:106675.
-
Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors. Indian J Pharmacol. 2021 May-Jun; 53(3):226-228.